MONDAY, 30 June
Program subject to change.
| 6:40 - 7:40 | EACPT Run and early morning
activities (Fabianinkatu 20 or Senate Square) | ||||||
| Participate with colleagues in the EACPT walk, run or yoga and get an energy boost for the second congress day | ||||||
| 8:20 - 9:00 | Keynote Lecture 2 (Great Hall) | ||||||
| Chair: Outi Lapatto-Reiniluoto, Helsinki University Hospital, Helsinki, Finland Climate change and its health dimensions Petteri Taalas, Director General, Finnish Meteorological Institute | ||||||
| 9:00 - 10:30 | Concurrent Sessions | |||||
| Session A3: Societal perspective of pharmacotherapy (Great Hall) Chairs: Katri Hämeen-Anttila, University of Eastern Finland, Kuopio, Finland and Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany | |||||
| 9:00 - 9:30 | Policies and strategies to enhance uptake of biosimilars Dorthe Bartels, Amgros I/S, Copenhagen, Denmark | ||||
| 9:30 - 10:00 | Financial burden of medicines for patients Katri Aaltonen, University of Turku, Turku, Finland | ||||
| 10:00 - 10:15 | Increasing use of gabapentinoids out of their authorised indications (Abstract O015) Caridad Pontes, Hospital De La Santa Creu I Sant Pau - Universitat Autònoma De Barcelona, Barcelona, Spain | ||||
| 10:15 - 10:30 | Polypharmacy in old patients before and after acute rehabilitation – an observational study in Western Pomerania (Abstract O016) Benedikt Eisenmann, University Greifswald, Departement of Clinical Pharmacology, Greifswald, Germany | ||||
| Session B4: Drug development beyond the era of small molecules (Auditorium) Chairs: Katriina Vuolteenaho, Tampere University, Tampere, Finland and Carolina Säll, Novo Nordisk, Copenhagen, Denmark | |||||
| 9:00 - 9:30 | Reflections on two decades of oligo ADME development Steve Hood, GSK, Stevenage, United Kingdom | ||||
| 9:30 - 10:00 | Can we utilize a small molecule strategy when developing therapeutic peptides? Carolina Säll, Novo Nordisk, Copenhagen, Denmark | ||||
| 10:00 - 10:15 | Relative and absolute bioavailability study of NXT007, a novel haemophilia A treatment, confirms patient flexibility between different injection sites (Abstract O017) Marion Anliker-Ort, F. Hoffmann-La Roche AG, Basel, Switzerland | ||||
| 10:15 - 10:30 | Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality (Abstract O018) Judith Verdonk, Radboudumc, Nijmegen, The Netherlands | ||||
| Session C4: Neurodegenerative diseases (Small Hall) Chairs: Mikko Airavaara, University of Helsinki, Helsinki, Finland and Dominique Deplanque, University of Lille, Lille, France | |||||
| 9:00 - 9:30 | Intra-cerebral administration of an anaerobic form of dopamine in Parkinson's disease: from experimental models to clinical development David Devos, University of Lille, Lille, France | ||||
| 9:30 - 10:00 | Parkinson's disease subtypes - does it impact pharmacological management? Filip Scheperjans, University of Helsinki, Helsinki, Finland | ||||
| 10:00 - 10:15 | Increased mortality in dementia patients using inhaled anticholinergics- a nationwide register study from the Swedish registry on dementia/cognitive disorders, SveDem (Abstract O019) Suzan Almayahi, Karolinska Institutet, Stockholm, Sweden | ||||
| 10:15 - 10:30 | CSF exposure of HER-096, a subcutaneously administered CDNF-peptidomimetic developed for Parkinson’s disease (Abstract O020) Kira Holmström, Herantis Pharma, Espoo, Finland | ||||
| 10:30 - 11:00 | Refreshment Break (Catering areas on 1st and 2nd floor) | |||||
| 11:00 - 12:30 | Concurrent Sessions | |||||
| Session A4: TDM: benefits and limitations (Small Hall) Chairs: Erik Eliasson, Karolinska Institutet, Stockholm, Sweden and Pierre Marquet, University of Limoges, Limoges, France | |||||
| 11:00 - 11:30 | The value of mycophenolate mofetil therapeutic drug monitoring for kidney transplant patients Pierre Marquet University of Limoges, Limoges, France | ||||
| 11:30 - 12:00 | Antimicrobial TDM in the critically ill Jason Roberts, University of Queensland, Brisbane, Australia | ||||
| 12:00 - 12:15 | Contribution of the gut microbiome to tacrolimus metabolism – a randomized phase I cross-over trial in healthy volunteers (Abstract O021) Katja Susanne Gümüs, Heidelberg University Hospital, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany | ||||
| 12:15 - 12:30 | Model-informed precision dosing of busulfan for children and adults undergoing allogeneic hematopoietic stem cell transplantation: a critical evaluation (Abstract O022) Rashudy Mahomedradja, Amsterdam UMC, Alkmaar, the Netherlands | ||||
| Session B5: Addressing unmet needs (Great Hall) Chairs: Timo Myöhänen, University of Helsinki, Helsinki, Finland and Caridad Pontes, Universitat Autónoma de Barcelona, Barcelona, Spain | |||||
| 11:00 - 11:30 | Where are we with the disease-modifying therapies for Parkinson’s disease Timo Myöhänen, University of Helsinki, Helsinki, Finland | ||||
| 11:30 - 12:00 | Model-informed drug development for rare diseases Piet van der Graaf, University of Leiden, The Netherlands | ||||
| 12:00 - 12:15 | GABAergic modulation in neuropathic pain patients: results of a randomized controlled trial with the α2-subunit preferring GABA modulator, N-desmethyl-clobazam (Abstract O023) Marie Besson, Geneva University Hospitals, Geneva, Switzerland | ||||
| 12:15 - 12:30 | Accelerating access to innovative therapies: a retrospective analysis of the EMA PRIME program (Abstract O024) Vanessa A. Prieto, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain | ||||
| Session C5: Chronic pulmonary diseases (Auditorium) Chairs: Jukka Mäenpää, Astra Zeneca, Gothenburg, Sweden and Clive Page, King's College London, London, United Kingdom | |||||
| 11:00 - 11:30 | Disease modifying treatments in early COPD Rod Hughes, AstraZeneca, Cambridge, United Kingdom | ||||
| 11:30 - 12:00 | Emerging drug targets in chronic pulmonary disease Clive Page, King's College London, London, United Kingdom | ||||
| 12:00 - 12:15 | Attitudes of patients with obstuctive pulmonary disease on the global warming impact of inhalers (Abstract O025) Olga Sič, Department Of Pharmacology, Toxicology And Clinical Pharmacology, Faculty Of Medicine Novi Sad, University Of Novi Sad, Novi Sad, Serbia | ||||
| 12:15 - 12:30 | Metformin as adjuvant therapy in pulmonary fibrosis: open label, randomised clinical trial (proof-of-concept study) (Abstract O026) Shivom Pratap, Aiims New Delhi, New Delhi, India | ||||
12:30 - 14:00 | Lunch and Poster ViewingLunch (Catering areas in 1st and 2nd floor) | |||||
| 13:00 - 14:00 | Presenters at posters P221-P245, P325-P357, P414-P429 |
| 14:00 - 15:30 pm | Concurrent Sessions | |||||
| Industry Sponsored Session A5: Medbase Symposium - Decision support tools in pharmacotherapy (Great Hall) Chairs: Maija Kaukonen, Medbase, Turku, Finland and Kari Laine, Medbase, Turku, Finland | |||||
| 14:00 - 14:30 | Decision support systems in optimizing pharmacotherapy: Evidence, challenges, and future directions Ylva Böttiger, Linköping University, Linköping, Sweden | ||||
| 14:30 - 15:00 | Transforming care through clinical decision support – the future is here Christoph U. Herborn, City Hospital Dessau, Dessau, Germany | ||||
| 15:00 - 15:15 | Medbase solutions for decision-making tools in pharmacotherapy Maija Kaukonen, Medbase, Turku, Finland | ||||
| 15:15 - 15:30 | Protocol for assessing drug interaction prevalence in Estonia through digital decision support integration (Abstract O027) Jana Lass, Tartu University Hospital, Tartu, Estonia | ||||
| Session B6: ADME biomarkers and extracellular vesicles: Phenotyping of drug metabolism, transport, and interactions (Auditorium) Chairs: Anne Filppula, Åbo Akademi University, Turku, Finland and Julia Stingl, University Hospital Heidelberg, Heidelberg, Germany | |||||
| 14:00 - 14:30 | Application of endogenous biomarkers and liquid biopsy in patients with renal impairment Alexandra Galetin, University of Manchester, Manchester, United Kingdom | ||||
| 14:30 - 15:00 | Phenotyping with biomarkers to model drug interactions Julia Stingl, University Hospital Heidelberg, Heidelberg, Germany | ||||
| 15:00 - 15:15 | Identification of endogenous substrates of ABC transporters using untargeted metabolomics (Abstract O028) Feng Deng, University of Helsinki, Helsinki, Finland | ||||
| 15:15 - 15:30 | Intra-individual and inter-individual expression of “major” and “minor” drug metabolizing enzymes along the length of the human intestine (Abstract O029) Stefan Oswald, Institute of Pharmacology and Toxicology, Rostock University Medical Center, Rostock, Germany | ||||
| Session C6: Vascular diseases (Small Hall) Chairs: Virpi Talman, University of Turku, Turku, Finland and Gerard Rongen, Radboud University Medical Center, Nijmegen, the Netherlands | |||||
| 14:00 - 14:30 | Lipid-lowering therapies - what is on the horizon for triglycerides and Lp(a)? Giuseppe Danilo Norata, University of Milan, Milan, Italy | ||||
| 14:30 - 15:00 | Is there a holy grail of anticoagulation without increased bleeding? Riitta Lassila, University of Helsinki, Helsinki, Finland | ||||
| 15:00 - 15:15 | A three-step static mechanistic approach to predicting complex interaction signals of direct oral anticoagulants (Abstract O030) Mostafa Schaat, University of Turku, Turku, Finland | ||||
| 15:15 - 15:30 | The association of CYP3A4, CYP3A5, ABCG2 and SLCO1B1 variants with atorvastatin-related ADRs and therapy switching: PGx-CardioDrug data (Abstract O031) Lana Ganoci, University of Zagreb School of Medicine, Zagreb, Croatia | ||||
| 15:30 - 16:00 | Refreshment Break (Catering areas on 1st and 2nd floor) | |||||
| 16:00 - 17:00 | EACPT General Assembly (Great Hall) Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands and EACPT Chairperson-elect Janne Backman, University of Helsinki, Helsinki, Finland EACPT members (those affiliated with a national member society) are welcome
| |||||
| 17:00 - 18:30 | Concurrent Sessions | |||||
| Sponsored Session: BCPT Nordic Symposium - Translational methods in drug metabolism and toxicity (Great Hall) Chairs, Aleksi Tornio, University of Turku, Turku, Finland and Ulf Simonsen, Aarhus University, Aarhus, Denmark | ||||
| 17:00 - 17:30 | Use of an in vivo like hepatic 3D spheroid model to study drug metabolism, drug hepatotoxicity, liver regeneration, hepatitis and MASH Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden | |||
| 17:30 - 18:00 | Translational aspects of biomarkers in chemotherapy-induced peripheral neuropathy Tore B. Stage, University of Southern Denmark, Odense, Denmark | |||
| 18:00 -18:15 | Grapefruit juice inhibits CYP2B6, CYP2C9, CYP2C19 and CYP3A4 while lingonberry powder does not affect major CYP enzymes in humans (Abstract O032) Laura Aurinsalo, University of Helsinki and Helsinki University Hospital, Helsinki, Finland | |||
| 18:15 - 18:30 | Non-targeted metabolomics for the identification of plasma metabolites associated with breast cancer resistance protein function (Abstract O033) Kreetta Hämäläinen, University of Helsinki, Helsinki, Finland | |||
| EASLDHILI & IUPHAR Session B7: Drug induced liver injury - Current topics (Auditorium) Chairs: Caroline Samer, University of Geneva, Geneva, Switzerland and M Isabel Lucena, University of Malaga, Malaga, Spain | ||||||
| 17:00 - 17:30 | Pharmacogenomics in DILI: A pathway to personalized precision medicine Ann Daly, University of Newcastle, Newcastle, United Kingdom | |||||
| 17:30 - 18:00 | Design, endpoints and challenges in conducting randomized clinical trials in DILI Yimin Mao, Shanghai Jiao Tong University, Shanghai, China | |||||
| 18:00 - 18:15 | Hepatic zonal distribution of OATP1B transporters and CYP enzymes affects simulated intracellular unbound concentrations of repaglinide and coproporphyrin I (Abstract O034) Marie-Noëlle Paludetto, University of Manchester, Centre For Applied Pharmacokinetic Research, Manchester, United Kingdom | |||||
| 18:15 - 18:30 | Liver-derived extracellular vesicles for multi-omics analysis of drug metabolism and liver disease (Abstract O035) Natalie Widmann, Dr. Margarete Fischer-bosch Institute Of Clinical Pharmacology, Stuttgart, Germany | |||||
| Workshop on Clinical Pharmacology for Teachers (Education Working Group) (Speaker Ready Room) Chairs: Joost Piët, Amsterdam UMC, Amsterdam, the Netherlands In this workshop you can contribute and brainstorm on how to improve and modernise CPT education | ||||||
| 17:00 - 18:30 | Clinical Pharmacology and Therapeutics Teach the
Teacher (CP4T) workshop: How to set up a student-assistant system for CPT education Joost Piët | |||||
| 17:00 - 18:30 | EACPT Council Meeting (for Councillors only) (Consistorium) Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands and EACPT Chairperson-elect Janne Backman, University of Helsinki, Helsinki, Finland | ||||||
| 19:15 - | Transportation to the Congress Dinner Restaurant (buses will leave from Senate Square starting at 19:15) 20:00 - | EACPT Congress Dinner at Restaurant Kalastajatorppa (separate ticket required) | ||||||